Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
NCT02639338
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
220
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C Virus Infection
Interventions
DRUG:
SOF/VEL/VOX
DRUG:
SOF/VEL
Sponsor
Gilead Sciences